ACOSOG is a cooperative group comprised of practicing medical, radiation, and surgical oncologists, diagnostic imagers, patient advocates, pathologists, basic scientists, nurses/CRAs, statisticians, and other healthcare professionals representing academic and community practices throughout the U.S. The purpose of ACOSOG is to develop and evaluate innovative cancer therapies in which the surgical management of cancer patients plays a key role. ACOSOG Is dedicated to Improving the care of the surgical oncology patient through an Innovative clinical research program addressing three specific aims: 1. To test novel therapies that may increase response and cure rates and reduce morbidities and disabilities associated with cancer care 2. To conduct basic science studies in conjunction with clinical trials to better understand the biologic basis of diseases and treatments. 3. To support Individual members and investigator networks to accrue patients to trials and fulfill the scientific mission of ACOSOG. The scientific portfolio of ACOSOG is focused on investigations addressing three scientific aims for ACOSOG trials: 1) to investigate novel surgical and targeted therapies to maintain oncologic outcomes while reducing toxicities and disabilities and Improving quality of life;2) to enhance the accuracy of risk stratification through imaging and molecular profiling;and 3) to Improve overall response rates and monitor Individual responses through the application of neoadjuvant therapies. The scientific agenda is established by the Basic and Translational Science Committee and the three Disease Committees: Breast, Gastrointestinal (GIST, pancreas, and rectum), and Thoracic (lung and esophagus) and maintained and prioritized by the ACOSOG Peer Review Committees. A multidisciplinary approach to the scientific agenda is accomplished through the comprehensive integration of all modalities and disciplines. Membership interests, needs, and oversight are attended to through the actions of seven Administrative Committees. To accomplish the goals of ACOSOG, the group conducts clinical trials and correlative studies using an infrastructure consisting of three critical components Including: 1) the Operations and Membership Center (OMC) located in Durham, NC, within the Duke Clinical Research Institute;2) the Statistics and Data Center (SDC) located In Rochester, MN, within the Mayo Clinic Cancer Center;and 3) the Central Specimen Bank (U24 # 5 U24 CA114736) located in St. Louis, MO, within the Washington University.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA076001-17
Application #
8397546
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1998-05-15
Project End
2014-11-30
Budget Start
2012-12-01
Budget End
2014-11-30
Support Year
17
Fiscal Year
2013
Total Cost
$2,940,780
Indirect Cost
$366,279
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Grogan, Eric L; Deppen, Stephen A; Ballman, Karla V et al. (2014) Accuracy of fluorodeoxyglucose-positron emission tomography within the clinical practice of the American College of Surgeons Oncology Group Z4031 trial to diagnose clinical stage I non-small cell lung cancer. Ann Thorac Surg 97:1142-8
Fernando, Hiran C; Landreneau, Rodney J; Mandrekar, Sumithra J et al. (2014) Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer. J Clin Oncol 32:2456-62
Boughey, Judy C; McCall, Linda M; Ballman, Karla V et al. (2014) Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg 260:608-14; discussion 614-6
Erdahl, Lillian M; Boughey, Judy C (2014) Use of sentinel lymph node biopsy to select patients for local-regional therapy after neoadjuvant chemotherapy. Curr Breast Cancer Rep 6:10-16
Corless, Christopher L; Ballman, Karla V; Antonescu, Cristina R et al. (2014) Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol 32:1563-70
Abrams, Jeffrey S; Mooney, Margaret M; Zwiebel, James A et al. (2013) Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst 105:954-9
DeMatteo, Ronald P; Ballman, Karla V; Antonescu, Cristina R et al. (2013) Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg 258:422-9
O'Flaherty, Joseph T; Wooten, Rhonda E; Samuel, Michael P et al. (2013) Fatty acid metabolites in rapidly proliferating breast cancer. PLoS One 8:e63076
Boughey, Judy C; Suman, Vera J; Mittendorf, Elizabeth A et al. (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310:1455-61
Garcia-Aguilar, Julio; Shi, Qian; Thomas Jr, Charles R et al. (2012) A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol 19:384-91

Showing the most recent 10 out of 42 publications